Summary
Pharma4Future is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €563,772 and a net result of €246,977. Equity is growing by about 85% per year across the filed financial years. Its solvency ranks better than 14% of 6,640 sector peers (NACE 64, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
02-04
Gazette deed
Permanent representative: Thomas ElpersResignation: Elpers Farma BV (director) · Director discharge7 facts ▸
- General meeting, 12-03-2026
- Permanent representative, Thomas Elpers
- Other provision, “vrijwillig ontslag bestuurder” (deed in Dutch)
- Director resignation, Elpers Farma BV (director)
- Other provision, “elk individueel, geen kwijting” (deed in Dutch) (3 times)
- Other provision, “kwijting, tussentijdse kwijting ontslagnemende bestuurder” (deed in Dutch)
- Director discharge, Elpers Farma BV (director)
About the unread acts
Of the 2 Belgian Official Gazette deeds we know for this company, 1 has been read. The other one has not been read yet: what they contain is neither established nor disproved here.